REGENXBIO Inc. (RGNX) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2022
Loading P/E history...
RGNX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, REGENXBIO Inc. (RGNX) trades at a price-to-earnings ratio of -2.3x, with a stock price of $10.42 and trailing twelve-month earnings per share of $-3.44.
The current P/E is 111% below its 5-year average of 20.1x. Over the past five years, RGNX's P/E has ranged from a low of 11.9x to a high of 33.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, RGNX trades at a 110% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, RGNX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RGNX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RGNX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 43.4 | - | +128%Best | |
| $358B | 85.5 | - | -1% | |
| $74B | 17.1Lowest | 2.70Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RGNX Historical P/E Data (2018–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $26.43 | $1.45 | 18.2x | -9% |
| FY2022 Q2 | $24.70 | $1.93 | 12.8x | -36% | |
| FY2022 Q1 | $33.19 | $2.15 | 15.4x | -23% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $32.70 | $2.74 | 11.9x | -41% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $41.95 | $2.89 | 14.5x | -28% |
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $75.50 | $2.27 | 33.3x | +65% |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $71.75 | $2.16 | 33.2x | +65% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $29.85 | $1.39 | 21.5x | +7% |
Average P/E for displayed period: 20.1x
See RGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGNX — Frequently Asked Questions
Quick answers to the most common questions about buying RGNX stock.
Is RGNX stock overvalued or undervalued?
RGNX trades at -2.3x P/E, below its 5-year average of 20.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RGNX's valuation compare to peers?
REGENXBIO Inc. P/E of -2.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is RGNX's PEG ratio?
RGNX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2022.